FDA’s drug approval backlog increases by 15% by Q3 2026

Regulatory uncertainty under interim leadership will slow down drug approvals, particularly for new treatments in high-priority areas like oncology. The agency’s review timelines will extend.

Implied probability (Yes)

65%